BioNTech Q2 2026: COVID sales drop 66% as oncology pivot weighs on results
As seen on the 24/7 Wall St. homepage on August 4, 2026.
COVID-19 vaccine sales fell 66% year over year, leaving total revenue of $105.6 million, missing expectations, as the oncology pivot absorbs the cost. Restructuring and write-downs pushed the operating loss to $948.1 million, with Phase 3 readouts for pumitamig, gotistobart and trastuzumab pamirtecan due in the second half of the year.
Continue ReadingShow less
BioNTech reported a Q2 2026 loss of $2.22 per share, missing the consensus estimate of $2.08 by about 6.8%. Total revenue came in at $105.6 million, well short of the $155.7 million analysts had expected, as the steep decline in COVID-19 vaccine sales — down 66% year over year — left a significant gap that the company's oncology programs are not yet filling.
The headline numbers were further pressured by restructuring charges and write-downs that pushed the operating loss to $948.1 million for the quarter. That figure reflects the real cost of pivoting away from a blockbuster vaccine franchise toward an early-stage oncology pipeline, a transition that requires heavy spending before any new product can generate meaningful revenue.
Sponsored
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
The key dates to watch are in the second half of 2026, when BioNTech expects Phase 3 readouts for three oncology candidates: pumitamig, gotistobart, and trastuzumab pamirtecan. Those results will be the clearest signal yet of whether the pipeline can eventually replace the COVID revenue the company has been losing. Looking back at recent quarters, EPS has missed estimates in several of the past eight periods, though the company did beat meaningfully in Q3 and Q4 2024.
Mentioned: BNTX